Galderma's new indication for Restylane Contour addresses a high-demand aesthetic concern and tightens competition in the volumization space.
Galderma received FDA approval for Restylane Contour for correction of temple hollowing, a common age-related volume loss that drives patient consultations but has lacked a cleared filler indication. Temple augmentation has been performed off-label with various HA and biostimulator products, but the cleared pathway reduces documentation burden and strengthens the clinical foundation for treatment.
Restylane Contour's particle size and rheology (designed for structural support and lift) make it mechanically suited to temple placement, where the goal is restoring volume in a relatively fixed anatomic pocket. The indication sits naturally within Galderma's volumization portfolio alongside Restylane Lyft and Restylane Defyne, allowing practices to sequence products by depth and clinical objective.
First cleared indication for temple hollowing correction using a hyaluronic acid filler.
For practices already stocked in Restylane, this is a straightforward expansion of use—no new product to inventory. The approval also signals Galderma's continued focus on anatomic specificity, a strategy that differentiates it from AbbVie's broader Juvéderm platform. Expect this to influence treatment planning and per-syringe allocation decisions.
Source: original report ↗
Frequently asked questions
Is Restylane Contour FDA approved for temple hollowing?
Yes. Galderma received FDA approval for Restylane Contour specifically for correction of temple hollowing, a common age-related volume loss. This is the first cleared filler indication for this anatomic concern, eliminating the need for off-label use.
What's the difference between Restylane Contour, Lyft, and Defyne for volumization?
Galderma's volumization portfolio is sequenced by depth and clinical objective. Restylane Contour is designed for structural support and lift in fixed anatomic pockets like temples, while Lyft and Defyne address deeper volume loss and contouring in other facial areas. Particle size and rheology differ to match each anatomic use.
Can you use Restylane Contour off-label for temple augmentation before the FDA approval?
Temple augmentation has been performed off-label with various HA and biostimulator products, but the new cleared indication reduces documentation burden and strengthens the clinical foundation for treatment. The approved pathway is now the standard of care.
Why is Restylane Contour better suited for temples than other fillers?
Restylane Contour's particle size and rheology are mechanically designed for structural support and lift in relatively fixed anatomic pockets like the temples. This specificity makes it more effective for restoring volume in this area compared to broader-use filler platforms.
Do I need to order new inventory for Restylane Contour temple treatment?
No. For practices already stocked in Restylane, this is a straightforward expansion of use—no new product to inventory. You can use existing Restylane Contour stock for temple hollowing correction.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
